Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more
Mereo BioPharma Group plc (MAH0) - Total Liabilities
Latest total liabilities as of September 2025: €7.00 Million EUR
Based on the latest financial reports, Mereo BioPharma Group plc (MAH0) has total liabilities worth €7.00 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mereo BioPharma Group plc - Total Liabilities Trend (2016–2024)
This chart illustrates how Mereo BioPharma Group plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mereo BioPharma Group plc Competitors by Total Liabilities
The table below lists competitors of Mereo BioPharma Group plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Financeira Alfa S.A. - Crédito Financiamento e Investimentos
SA:CRIV3
|
Brazil | R$16.29 Billion |
|
Northern Ocean Ltd
PINK:NTNOF
|
USA | $662.45 Million |
|
Cheng Fwa Industrial Ltd
TWO:5426
|
Taiwan | NT$854.89 Million |
|
1895 of Wisconsin Inc Bancorp
NASDAQ:BCOW
|
USA | $546.41 Million |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$6.29 Million |
|
River Valley Community Bancorp
PINK:RVCB
|
USA | $552.79 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Mereo BioPharma Group plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mereo BioPharma Group plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mereo BioPharma Group plc (2016–2024)
The table below shows the annual total liabilities of Mereo BioPharma Group plc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €15.42 Million | -3.39% |
| 2023-12-31 | €15.96 Million | -39.10% |
| 2022-12-31 | €26.21 Million | -31.77% |
| 2021-12-31 | €38.41 Million | -50.70% |
| 2020-12-31 | €77.92 Million | +68.68% |
| 2019-12-31 | €46.19 Million | +33.87% |
| 2018-12-31 | €34.51 Million | +1.93% |
| 2017-12-31 | €33.85 Million | +350.87% |
| 2016-12-31 | €7.51 Million | -- |